Tech Company Financing Transactions
Hallux Funding Round
Hallux closed a $7.1 million Series A funding round on 12/18/2015. Backers included Deerfield Capital and private investors.
Transaction Overview
Company Name
Announced On
12/18/2015
Transaction Type
Venture Equity
Amount
$7,100,000
Round
Series A
Investors
Deerfield Capital (Lead Investor)
Proceeds Purpose
The new capital will be deployed to advance Hallux's proprietary terbinafine micro-insert dosage form into phase 2A clinical trials, with the goal of demonstrating safety, efficacy, and tolerability in patients with distal lateral subungual onychomycosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
23052 Alcalde Dr. A
Laguna Hills, CA 92653
USA
Laguna Hills, CA 92653
USA
Phone
Website
Email Address
Overview
Hallux, Inc. is a privately held clinical-stage pharmaceutical company focused on developing its lead product candidate HTS (Hallux Terbinafine Sublingual).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Taylor
Co-Founder
Jay Birnbaum
Browse more venture capital transactions:
Prev: 12/18/2015: WellDoc venture capital transaction
Next: 12/18/2015: Unitiv venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs